[{"id":"99889667-7df9-4ba0-9746-9b7586ccaa67","acronym":"","url":"https://clinicaltrials.gov/study/NCT05779917","created_at":"2023-03-22T14:03:05.395Z","updated_at":"2024-07-02T16:35:29.095Z","phase":"Phase 1","brief_title":"Mesothelin/GPC3/GUCY2C-CAR-T Cells Against Cancers","source_id_and_acronym":"NCT05779917","lead_sponsor":"Second Affiliated Hospital of Guangzhou Medical University","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN expression • MSLN positive","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression • MSLN positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mesothelin/GPC3/GUCY2C-CAR-T"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 03/10/2023","start_date":" 03/10/2023","primary_txt":" Primary completion: 03/10/2026","primary_completion_date":" 03/10/2026","study_txt":" Completion: 03/10/2033","study_completion_date":" 03/10/2033","last_update_posted":"2023-11-15"},{"id":"0e2c53e2-5daa-4613-9cf4-4a3a1038b338","acronym":"","url":"https://clinicaltrials.gov/study/NCT03198052","created_at":"2021-01-18T15:46:10.109Z","updated_at":"2024-07-02T16:35:55.664Z","phase":"Phase 1","brief_title":"GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T Cells Against Cancers","source_id_and_acronym":"NCT03198052","lead_sponsor":"Second Affiliated Hospital of Guangzhou Medical University","biomarkers":" EGFR • HER-2 • CLDN18 • AXL • MSLN • MUC1 • CD276 • GPC3 • GUCY2C • PSCA","pipe":" | ","alterations":" MSLN expression • EGFR positive • GPC3 expression","tags":["EGFR • HER-2 • CLDN18 • AXL • MSLN • MUC1 • CD276 • GPC3 • GUCY2C • PSCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression • EGFR positive • GPC3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T cells"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/01/2017","start_date":" 07/01/2017","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2023-02-14"},{"id":"1ad5d82f-356d-48a2-a7b8-f01f8efc481e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05287165","created_at":"2023-10-19T11:12:17.844Z","updated_at":"2024-07-02T16:36:15.147Z","phase":"Phase 1","brief_title":"Clinical Trial to Evaluate the Safety and Efficacy of IM96 CAR-T Cells Therapy in Patients With Advanced Digestive System Neoplasms","source_id_and_acronym":"NCT05287165","lead_sponsor":"Beijing Immunochina Medical Science \u0026 Technology Co., Ltd.","biomarkers":" GUCY2C","pipe":"","alterations":" ","tags":["GUCY2C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IM96 CAR-T cells"],"overall_status":"Recruiting","enrollment":" Enrollment 19","initiation":"Initiation: 03/10/2022","start_date":" 03/10/2022","primary_txt":" Primary completion: 04/30/2024","primary_completion_date":" 04/30/2024","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2022-03-18"}]